Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the gut microbiota composition in patients with post-finasteride syndrome differs significantly from healthy controls, with reduced diversity and specific microbial changes, suggesting a potential diagnostic marker and therapeutic target.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

In this review, extensive analysis using conditional mutant mice revealed that androgen and Wnt signals play crucial roles in the development and function of male external genitalia and erectile tissue, while also exploring various regulatory factors involved in their pathogenesis.

This review discusses the classification and treatment of ejaculatory dysfunction, outlining both pharmacotherapy and behavioral therapy as primary interventions, but does not present new clinical findings.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.

In this animal study, finasteride treatment altered testosterone metabolism in rat corpus cavernosum, linked to mechanisms of erectile dysfunction, but these changes were reversed after stopping the drug, suggesting post-treatment sexual side effects may relate more to central control dysfunction than peripheral issues.

This study identified specific genes and pathways in human Leydig cells that may contribute to Post-finasteride Syndrome, potentially informing future treatments to reverse persistent side effects.

The authors describe drug repurposing as a promising strategy for finding new uses for existing drugs, noting it is efficient, cost-effective, and poses lower risks than traditional drug discovery processes, potentially aiding in the treatment of rare and difficult-to-treat diseases.

This review discusses how various reproductive factors are linked to increased risks of hypertension and cardiovascular disease, noting associations with impaired fetal growth, male hypogonadism, and effects of contraceptive use, but reports no new results.

This review focuses on recent advancements in understanding and treating ischemic and nonischemic priapism, but does not present new clinical results.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This review examines the placebo response in conditions such as allergies and weight loss, highlighting its significance in both conventional and alternative medicine randomized trials, without reporting any new results.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

This review discusses methods for improving study design and evaluation in sexual health literature and reports no new clinical results; it highlights current methodological issues and the benefits of validated questionnaires.

This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

This review highlights that drug repositioning offers a cost-effective alternative to traditional drug discovery, especially for treating orphan and resistant diseases like COVID-19, by repurposing existing drugs such as Hydroxychloroquine and Remdesivir.

This consensus document reviews current knowledge on sex differences in essential hypertension and identifies areas needing further research to improve sex-specific prevention and management strategies.

This review discusses current medical therapies available for treating hair loss and emphasizes the importance of understanding these options, but it presents no new results.

This review discusses post-SSRI sexual dysfunction syndrome and highlights its significant clinical and regulatory implications, but reports no new findings.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

This study evaluated potential penile vascular changes and persistent adverse effects in men discontinuing 5α-reductase inhibitors for androgenic alopecia, but no new clinical results were reported.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

The researchers reported that using Natesto® testosterone gel improved erectile function and mood in hypogonadal men over a 90-day period.

Many women experience sexual dysfunction, but few seek help, and better treatment and medical training are needed.

In this study, oral finasteride treatment for four weeks reduced the weight of the corpus cavernosum in rats but did not significantly affect erectile function.

This study reported a significant increase in the reporting of sexual dysfunction associated with finasteride use, especially in individuals aged 31-45.

This review discusses treatments for female sexual dysfunction in postmenopausal women, noting that the effectiveness of current pharmaceutical options is inconclusive and emphasizing the importance of individualized care.